Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12431998 | 0.89 | HDAC1 (0.49) | HDAC1HDAC8HDAC3HDAC2HDAC7 | |
| SCHEMBL1377385 | 0.86 | HDAC1 (0.65) | HDAC1HDAC8HDAC3HDAC2HDAC7 | |
| SCHEMBL1375273 | 0.83 | HDAC1 (0.64) | HDAC1HDAC8HDAC3HDAC2HDAC7 | |
| SCHEMBL1373472 | 0.81 | HDAC1 (0.66) | HDAC1HDAC8 | |
| SCHEMBL1374669 | 0.78 | HDAC1 (0.67) | HDAC1HDAC8HDAC3HDAC2HDAC7 | |
| SCHEMBL7829868 | 0.78 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC7 | |
| SCHEMBL3378763 | 0.78 | HDAC1 (1.00) | HDAC1HDAC8HDAC3HDAC2HDAC7 | |
| SCHEMBL1374163 | 0.77 | HRH3 (0.56) | HDAC1HDAC8HDAC3HDAC2HDAC7 | |
| SCHEMBL8007652 | 0.77 | MAPT (0.61) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL9410731 | 0.77 | GPR183 (0.56) | HDAC1HDAC8HDAC3HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275810-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| US-20110275810-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| US-20110275810-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| US-7981895-B2 | Histone deacetylase inhibitor; anticancer agents; antiproliferative agents; antitumor agents; psoriasis; piperazine compound containing a carbamic acid group | TOPOTARGET UK LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-7981895-B2 | Histone deacetylase inhibitor; anticancer agents; antiproliferative agents; antitumor agents; psoriasis; piperazine compound containing a carbamic acid group | TOPOTARGET UK LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-7981895-B2 | Histone deacetylase inhibitor; anticancer agents; antiproliferative agents; antitumor agents; psoriasis; piperazine compound containing a carbamic acid group | TOPOTARGET UK LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-7629343-B2 | Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629343-B2 | Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629343-B2 | Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1492534-B1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2008-06-25 | — | — | EP | disclosed |
| EP-1492534-B1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2008-06-25 | — | — | EP | disclosed |
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| EP-1492534-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082288-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | HDAC1, HDAC7, HDAC11 | HDAC1 1/4885HDAC8 7/4885HDAC3 5/4885 |
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | HDAC5, HDAC1, HDAC7 | HDAC1 2/4885HDAC8 8/4885HDAC3 7/4885 |
| US-20110275810-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | HDAC5, HDAC1, HDAC7 | HDAC1 2/4885HDAC8 8/4885HDAC3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.